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Abstract
OBJECTIVES: Transcatheter aortic valve replacement (TAVR) provides good results in selected high-risk patients. However, it is unclear
whether this procedure carries advantages in extreme-risk proﬁle patients with logistic EuroSCORE above 35%.
METHODS: From January 2009 to July 2011, of a total number of 92 transcatheter aortic valve procedures performed, 40 ‘extreme-risk’
patients underwent transapical TAVR (TA-TAVR) (EuroSCORE above 35%). Variables were analysed as risk factors for hospital and mid-
term mortality, and a 2-year follow-up (FU) was obtained.
RESULTS: The mean age was: 81 ± 10 years. Twelve patients (30%) had chronic pulmonary disease, 32 (80%) severe peripheral vascular
disease, 14 (35%) previous cardiac surgery, 19 (48%) chronic renal failure (2 in dialysis), 7 (17%) previous stroke (1 with disabilities), 3
(7%) a porcelain aorta and 12 (30%) were urgent cases. Mean left ventricle ejection fraction (LVEF) was 49 ± 13%, and mean logistic
EuroSCORE was 48 ± 11%. Forty stent-valves were successfully implanted with six Grade-1 and one Grade-2 paravalvular leakages
(success rate: 100%). Hospital mortality was 20% (8 patients). Causes of death following the valve academic research consortium (VARC)
deﬁnitions were: life-threatening haemorrhage (1), myocardial infarction (1), sudden death (1), multiorgan failure (2), stroke (1) and
severe respiratory dysfunction (2). Major complications (VARC deﬁnitions) were: myocardial infarction for left coronary ostium occlusion
(1), life-threatening bleeding (2), stroke (2) and acute kidney injury with dialysis (2). Predictors for hospital mortality were: conversion to
sternotomy, life-threatening haemorrhage, postoperative dialysis and long intensive care unit (ICU) stay. Variables associated with hos-
pital mortality were: conversion to sternotomy (P = 0.03), life-threatening bleeding (P = 0.02), acute kidney injury with dialysis (P = 0.03)
and prolonged ICU stay (P = 0.02). Mean FU time was 24 months: actuarial survival estimates for all-cause mortality at 6 months, 1 year,
18 months and 2 years were 68, 57, 54 and 54%, respectively. Patients still alive at FU were in good clinical condition, New York Heart
Association (NYHA) class 1–2 and were never rehospitalized for cardiac decompensation.
CONCLUSIONS: TA-TAVR in extreme-risk patients carries a moderate risk of hospital mortality. Severe comorbidities and presence of
residual paravalvular leakages affect the mid-term survival, whereas surviving patients have an acceptable quality of life without rehos-
pitalizations for cardiac decompensation.
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INTRODUCTION
Degenerative aortic valve stenosis (AS) occurs in the elderly and
represents the most frequent acquired heart valve disease in devel-
oped countries [1, 2]. Because of the ageing population, the amount
of elderly patients with aortic stenosis and severe comorbidities
(‘high-risk’ and ‘extreme-risk’ proﬁles) is increasing constantly.
Surgery for aortic valve replacement (AVR) with cardiopulmonary
bypass (CPB), aortic cross clamping and cardioplegic cardiac arrest
remains the treatment of choice in case of symptomatic AS and
offers the potential for improved survival with excellent
postoperative outcomes [3–5]. However, recently, patients at too
high a risk for conventional surgery (logistic EuroSCORE > 20%) have
been scheduled for transcatheter AVRs (TAVR) with stented-valves
implanted on a beating heart and through minimally invasive
accesses [6–8]. Results are good, but it is still unclear if the expected
beneﬁts of this technology are present when ‘extreme-risk’ proﬁle
patients with logistic EuroSCORE superior to 35%, are concerned.
We retrospectively selected a group of extreme-risk proﬁle
patients operated on for transapical TAVR (TA-TAVR) in our insti-
tution using the Sapien™ valve platform (Edwards Lifesciences
Inc., Irvine, CA, USA), analysed outcomes and mid-term results
(16 months of follow-up (FU)) and identiﬁed the risk factors for
hospital and mid-term mortalities.†Both authors contributed equally to this work.
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MATERIALS AND METHODS
Study design
Using our transcatheter aortic valve registry, we identiﬁed
patients with extreme-risk proﬁles who underwent aortic repla-
cements from January 2009 to July 2011 (from 92 consecutive
transcatheter aortic valve procedures performed, including 70
transapical and 22 transfemoral). All extreme-risk proﬁle patients
were in the transapical group.
The ‘extreme-risk’ proﬁle was deﬁned as follows: an elderly
patient with severe symptomatic AS and predicted surgical mor-
tality equal or superior to 35% (calculated by logistic
EuroSCORE), with at least three concomitant EuroSCORE vari-
ables collected in the record. As to the choice of the EuroSCORE
risk score system (www.euroscore.org), it represents a simple and
intuitive tool for simplifying and standardizing the decision-
making process for TAVR, and is routinely employed in our insti-
tution and in the majority of European hospitals.
Clinical data were collected, analysed and studied as risk
factors for hospital mortality, all-cause mid-term mortality and
cardiovascular mortality. A mid-term FU was obtained (mean
time: 24 months; full term: 100%).
Transapical TAVR
All procedures were performed with balloon-expandable
Sapien™ and Sapien-XT™ stent-valves (Edwards Lifesciences,
Irvine, CA, USA) following standard guidelines [9]. In patients
with impaired kidney function, we did not use contrast [10]. In
one case, a redo patient with impaired left ventricular function
(LVEF: 30%) and patent coronary bypasses, a femoro-femoral
CPB was instituted before the procedure in order to decrease
the risk of haemodynamic instability following the rapid pacing
(preoperative strategic plan). All procedures were performed
under general anaesthesia, in the operating room, by a team of
dedicated cardiac surgeons, cardiologists and anaesthesiologists
and using a high-quality C-arm ﬂuoroscopic machine and a
transoesophageal echocardiographic imaging system. All cases
were discussed by a multidisciplinary team and all patients signed
an informed consent. After the procedure, patients were placed
on anticoagulation treatment for 3 months (following the protocol
in use for standard bioprosthesis) plus aspirin (100 mg/day).
Statistical analysis
The statistical analysis was performed using the STATA 12.0 Data
Analysis and Statistical Software package for Windows (StataCorp
LP, College Station, TX, USA). Continuous variables are presented
as mean ± one standard deviation (SD) where normally distribu-
ted, and as median and inter-quartile range if not normally dis-
tributed. Categorical variables are given as frequencies and
percentages (%). Selected preoperative, intraoperative and post-
operative variables were analysed as risk factors for hospital
mortality (any death occurring within 30 days of the operation
or death during the same hospital admission) using the Fisher’s
exact test. To identify predictors for hospital mortality (all death
confounded and only cardiovascular death) and for mortality
during the FU time (all-cause mortality and cardiovascular mor-
tality), survival curves were computed using the Kaplan–Meier
method [log-rank tests or Wilcoxon (Breslow) test for equality of
survivor functions depending on the number of events]. For the
Table 1: Baseline characteristics
Characteristics TA-TAVR (n = 40) P for hospital mortality
Age (years) 81 ± 10 (range: 54–95)
Sex, female 27 (67)
Logistic EuroSCORE (%) 48 ± 11 (range: 35–77)
Risk factors and comorbidities
Coronary disease (any) 25 (62) 1.00
Peripheral vascular disease (severe) 32 (80) 1.00
Hypertension 21 (52) 1.00
Diabetes (type 1) 9 (22) 1.00
BMI < 20 6 (15) 0.35
COPD (any) 12 (30) 0.67
Previous stroke 7 (17) 0.61
Porcelain aorta (at CT-scan) 3 (7) 1.00
Chronic kidney failure 19 (48) 0.69
Chronic haemodialysis 2 (5) 1.00
Previous thoracic radiotherapy 4 (10) 1.00
Critical state (hospitalization in intermediate or ICU with drug infusions) 12 (30) 1.00
Cardiac history
Previous cardiac surgery 14 (35) 1.00
Previous CABG 10 (25) 1.00
Previous aortic bioprosthesis 5 (13) 1.00
Previous PCI/stenting 7 (17) 0.13
Previous pacemaker implantation 3 (7) 1.00
TA-TAVR: transapical transcatheter aortic valve replacement; BMI: body mass index; COPD: chronic obstructive pulmonary disease; CABG: coronary artery
bypass grafting; PCI: percutaneous coronary intervention.
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all death confounded, a Cox regression model was also run with
the best predictors deﬁned through the Kaplan–Meier analysis. A
P-value <0.05 was considered signiﬁcant. Authors had full access
to, and take full responsibility for the integrity of the data.
RESULTS
Of the 92 consecutive transcatheter aortic valve procedures per-
formed, we identiﬁed 40 elderly patients with logistic
EuroSCORE superior or equal to 35% plus, at least 3 concomitant
EuroSCORE variables collected in the record. Preoperative char-
acteristics are listed in Table 1.
Speciﬁcally, the mean EuroSCORE was 48 ± 11%, with 32
patients (80%) suffering from severe peripheral vascular disease
contra-indicating transfemoral transcatheter procedures (all
patients showed severe advanced aortic atherosclerosis at com-
puted tomography (CT)-scan and transoesophageal echocardio-
gram). The vascular assessment was performed under angio
CT-scan and Doppler for the aorta and carotid arteries, and the
subclavian access was never used in our hospital (‘off-label’ use
with the Edwards Sapien™ platform at that time). Seven patients
had a history of stroke and one carried impaired left arm motil-
ity as residual disability. With regard to cardiac diseases, 14
patients (35%) had previous cardiac surgery and 5 a concomitant
implantation of an aortic bioprosthesis (3 Sorin Mitroﬂow™ (21,
23 and 25 mm) and 2 Edwards Perimount® (23 and 25 mm)) [11].
Severe coronary disease was previously diagnosed and treated in
15 patients (37%), with surgery for coronary revascularization in
10, and percutaneous procedure in 7. Nineteen patients (48%)
suffered from chronic kidney insufﬁciency (chronic increase of
blood creatinine level of at least double the standard limits, fol-
lowing the RIFLE classiﬁcation), and 2 were already under inter-
mittent haemodialysis: in the whole group of extreme-risk
patients, the mean blood preoperative creatinine and urea levels
were 108 ± 54 μmol/l and 12 ± 7 mmol/l, respectively (ranges in
our hospital: creatinine 62–106 μmol/l; urea 3–7 mmol/l).
Concerning their preoperative clinical state, 12 patients (30%)
were critical, with signs of cardiac failure requiring surveillance
in the mid-care or intensive-care unit and drug infusions or, in
one case, intubation (low cardiac output due to late stage AS).
From an echocardiographic point of view (Table 2), the mean
LVEF was 49 ± 13%, the mean trans-valvular peak gradient was
63 ± 25 mmHg, the calculated oriﬁce area was 0.6 ± 0.2 cm2
(indexed: 0.4 ± 0.1 cm2/m2) and 23 patients (57%) suffered from
chronic pulmonary hypertension (pulmonary artery systolic pres-
sure above 50 mmHg). All patients showed severe AS except
one, a ‘valve-in-valve’ patient, where the degenerated aortic bio-
prosthesis was severely incompetent.
Intraoperatively, 40 Sapien™ stent-valves were placed correctly
[procedural success rate according to the valve academic re-
search consortium (VARC) deﬁnition: 100%] with a mean stent-
valve diameter of 24 ± 2 mm; (22 valves: 23 mm; 17 valves: 26
mm; and 1 valve: 29 mm) corresponding to a measured mean
aortic annulus of 23 ± 2 and 22 ± 2 mm at CT-scan and transoe-
sophageal echocardiogram imaging, respectively (Tables 2 and
3). CPB support was required three times: in a coronary redo
case with low LVEF, the CPB was established before the proced-
ure to sustain the haemodynamic status during the rapid pacing
phases (femoro-femoral cannulation in a patient with tortuous
femoral arteries and previous peripheral vascular surgery); in
two more cases CPB was urgently instituted to treat life-
threatening haemorrhages (from the apex and from the left ven-
tricle). With respect to CPB use, although patients are at
extreme-risk or inoperable, we maintain the machine on
stand-by, and its usage is justiﬁed when severe bleedings occur:
once the patient is haemodynamically stable and the left ven-
tricle is unloaded, the apical haemostasis becomes easier and, in
the mean time, the lost blood is rapidly reinfused. Nevertheless,
CPB strongly depends on the availability of cannulation sites, this
being determined prior to surgery, and requires a prompt reac-
tion from the entire team.
The mean procedural time was 95 ± 29 min and 13 patients
were extubated in the operating room. Two patients died on the
operating table: the ﬁrst, an 84-year-old female, died from a life-
threatening haemorrhage originating from a tear in the left ven-
tricle (after surgical repair we were unable to wean the CPB
support), whereas the second patient, also a frail 88-year-old
female with a 19-mm aortic annulus, died from an irreversible
occlusion of the left coronary ostium with consequent intrapro-
cedural myocardial infarction and cardiac arrest: the stent-valve
displaced the severely calciﬁed left coronary leaﬂet against the
aortic wall and, despite the sternotomy and the attempt to insti-
tute a CPB support, the haemodynamic status deteriorated
rapidly and irreversibly.
At echocardiography, we had one Grade 2 (severe annular calci-
ﬁcations) and six Grade 1 paravalvular leakages with a mean trans-
valvular mean gradient of 11 ± 5 mmHg. In the subgroup of ﬁve
patients with ‘valve-in-valve’ treatments, the mean trans-valvular
mean gradient was 20 ± 6 mmHg and the patient carrying the
smallest bioprosthesis (the 21 mm Sorin Mitroﬂow™) had peak and
mean gradients of 28 and 17 mmHg, respectively [11, 12].
Hospital mortality was 20% (in total eight patients died; six
within 30 days) and cardiovascular causes of death, according to
the VARC deﬁnition, were four: one intraprocedural life-
threatening ventricular haemorrhage requiring CPB and surgical
repair of the tear, ending up with severe irreversible ventricular




Mean LVEF (%) 49 ± 13
LVEF 0–30% 4 (10)
LVEF 30–50% 17 (45)
LVEF > 50% 17 (45)
Mean EOA (cm²) 0.6 ± 0.2
Mean trans-valvular peak gradient (mmHg) 65 ± 25
Pulmonary hypertension (>50 mmHg) 23 (57)
Mean aortic annulus diameter at TEE (mm) 22 ± 2
Mean aortic annulus diameter at CT-scan (mm) 23 ± 2
Mean aortic annulus-LCA distance (mm) 11 ± 2
Mean aortic annulus-RCA distance (mm) 12 ± 3
Pure degenerative AS 39 (97)
Pure valve regurgitation (in a degenerated
bioprosthesis)
1 (3)
TA-TAVR: transapical aortic valve replacement; LVEF: left ventricle
ejection fraction; EOA: effective orifice area; TTE: transthoracic
echocardiogram; TEE: transeosophageal echocardiogram; CT:
computed tomography; LCA: left coronary artery; RCA: right coronary
artery; AS: aortic valve stenosis.
Data are presented as mean ± SD or number (%).
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dysfunction; one intraprocedural myocardial infarction for left
coronary ostium obstruction; one sudden death at postoperative
day 12 (probably a pulmonary oedema due to a peak of blood
pressure in systemic hypertension) and one severe stroke follow-
ing intraoperative hypotension in a coronary redo case who
required reanimation manoeuvres after the rapid cardiac pacing.
Two more patients died of multiorgan failure (MOF) during the
intensive care unit (ICU) stay and two frail old female patients
(cachexia) died of severe respiratory dysfunction in pneumonia.
Following the VARC deﬁnitions for postoperative complica-
tions during TAVR procedures, we also had one patient who had
an apical life-threatening bleeding successfully treated under
CPB, two (5%) who suffered from acute kidney injury requiring
continuous haemoﬁltration (RIFLE classiﬁcation stage 3), one
with a stroke with haemiplegia at postoperative day 9 despite
the anticoagulation treatment and aspirin, and patients requiring
deﬁnitive pacemakers for Grade 3 atrio-ventricular-block
(Tables 3 and 4, Fig. 1).
Concerning the predictors for hospital mortality, we did not
ﬁnd preoperative variables that predicted hospital mortality
(limited number of patients in this cohort). However, some intra-
and postoperative complications were statistically signiﬁcant
to predict hospital mortality (P < 0.05): conversion to sternotomy
(P = 0.03), intraoperative life-threatening bleeding (P = 0.02),
postoperative acute kidney injury with dialysis (P = 0.03) and pro-
longed ICU stay (P = 0.02). The rapid extubation within 5 h of
surgery was a positive predictor for lower risk of hospital mortal-
ity (P = 0.02).
FU was performed in May 2012 and the mean FU time was 24
months (Table 5). Among the 32 patients who were discharged,
20 were still alive and 12 deceased. The cause of death was car-
diovascular in 10 patients (cardiovascular mortality: 31%): 7
documented cardiac failures, 1 cardiac arrest and 2 cerebral hae-
morrhages. The actuarial survival estimates from cardiovascular
mortality at 6 months, 1 year, 18 months and 2 years were 90,
77, 73 and 73%, respectively (Fig. 2A). MOF and pneumonia
were causes of death in two more patients (all-cause mortality at
FU: 37%). The 20 patients still alive were all in good clinical con-
dition, with respect to their age, and were all in New York Heart
Association (NYHA) class 1–2 without history of rehospitalization
for cardiac decompensation: to note, this includes the 2 patients
on preoperative chronic haemodialysis and 4 ‘valve-in-valve’
cases. Signs of valve dysfunction were not reported. The actuarial
survival estimates from all-cause confounded mortality at 6
months, 1 year, 18 months and 2 years are 68, 57, 54 and 54%,
respectively (Fig. 2B).
Concerning the risk factors for all-cause mortality at FU, we
analysed the same variables we used for the hospital mortality
and our ﬁndings are that there were one preprocedural and two
postprocedural variables with statistical relevance: the presence
of previous coronary angioplasty/stent (P = 0.01) and the pres-
ence of a postoperative paravalvular leak (P = 0.02) were
Table 3: Clinical operative results
Variables TA-TAVR (n = 40) P for hospital mortality
Successful procedure (one correctly implanted stent-valve and system retrieval) 40 (100%)
Valve-in-valve procedure (VinV) 5 (13) 1.00
Redo surgery 14 (35) 1.00
Conversion to sternotomy 2 (5) 0.03
IABP support 0
CPB use 3 (7) 0.09
Mean procedural time (min) 95 ± 29
Mean stent-valve diameter (mm) 22× a 23 mm; 17× a 26 mm; 1× a 29 mm) 24 ± 2
Surgical outcome and complications
Valve embolization 0
Valve malfunctioning 0
Paravalvular leak (Grade 1 = 6; Grade 2 = 1) 7 (17) 0.13
Trans-valvular mean gradient (mmHg) 11 ± 5
Myocardial infarction (left coronary ostium obstruction) 1 (2) 0.26
Life-threatening bleeding (one apical and one ventricular) 2 (5) 0.02
Rethoracotomy for minor haemostasis 1 (2) 1.00
Early extubation (up to 5 h postoperatively) 33 (82) 0.02
On-table extubation 13 (32) 1.00
Long ICU stay, long intubation, tracheotomy 2 (5) 0.02
Acute kidney injury (RIFLE stage 3) 2 (5) 0.03
Pacemaker implantation for BAV3 2 (5) 1.00
Pneumonia 3 (7) 0.56
Stroke 2 (5) 0.46
ICU stay (days) 3 ± 7 (median = 1; IQR = 1)
Hospital stay (days) 16 ± 11(median = 12; IQR = 6)
Mortality
Intraprocedural death 2 (5)
Thirty-day mortality 6 (15)
In-hospital mortality 8 (20)
TA-TAVR: transapical aortic valve replacement; IABP: intra-aortic balloon pump; CPB: cardiopulmonary bypass; ICU: intensive care unit; IQR: inter-quartile
range.
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identiﬁed as risk factors for late mortality (Fig. 3A and B),
whereas the early extubation had a positive impact on long-term
survival (P = 0.03). The multivariate analysis applied to the vari-
ables ‘previous coronary stenting’ and ‘postoperative paravalvular
leak’ (Cox regression model) showed a 3.6 times and a 3 times
higher risk of long-term all-cause mortality, respectively, for
patients having these characteristics.
With regard to the risk factors for late cardiovascular mortality,
we identiﬁed variables with statistical signiﬁcance: systemic
hypertension (P < 0.00), previous coronary bypass grafting
(P = 0.02), previous coronary angioplasty/stent (P = 0.01) (Fig. 3C)
and postoperative paravalvular leak (P = 0.01) (Fig. 3D).
DISCUSSION
TAVR is a minimally invasive technique for elderly patients with
symptomatic AS and at high-risk for conventional surgery.
Moreover, those with an ‘extreme-risk’ proﬁle are very fragile
elderly patients with a very poor outcome in the absence of
appropriate treatment, and we were interested in evaluating the
efﬁcacy of transcatheter aortic valve procedures in this selected
subgroup of patients.
Although TAVR procedures in high-risk patients with logistic
EuroSCORE around 20% have already shown good hospital out-
comes with 1-year mortality rates ranging from 25 to 30%
Figure 2: (A) Kaplan–Meier survival estimate for cardiovascular mortality [with
conﬁdence intervals (95% CI) in blue]. (B) Kaplan–Meier survival estimate for
all-cause mortality (with 95% CI in blue).
Figure 1: Hospital outcome: clinical endpoints following the VARC deﬁnition.
(Standardized endpoints for transcatheter aortic valve implantation clinical
trials: a consensus report from the Valve Academic Research Consortium. Eur
Heart J 2011;32:205–217.)
Table 5: Follow-up (32 discharged patients)
Variables TA-TAVR (n = 32)
Mean FU time (months) 24 (range 9–40)
FU completeness 100%
Patients alive at FU 20 (63)
All-cause mortality 12 (37)
Cardiovascular mortality (cardiac failure: 7;
cardiac arrest: 1; cerebrovascular accident: 2)
10 (31)
Other cause of death
MOF (in sepsis) 1 (3)
Pneumonia 1 (3)
Valve dysfunction 0
Valve-related cardiovascular procedures 0
TA-TAVR: transapical aortic valve replacement; FU: follow-up; MOF:
multiorgan failure.
Data are presented as mean ± SD or number (%).
Table 4: Clinical endpoints following the VARCa
definitions, n = 40
Device success 40 (100)
All-cause mortality 8 (20)
Cardiovascular mortality 4 (10)
Myocardial infarction (periprocedural) 1 (2.5)
Stroke (major) 2 (5)
Bleeding (life-threatening) 2 (5)
Access site complications (vascular—major) 1 (2.5)
Acute kidney injury (RIFLE 3) 2 (5)
PVL (moderate/severe) 1 (2.5)
Valve-related failure/dysfunction 0
PVL: paravalvular leak.
Data are presented as mean ± SD or number (%).
aStandardized endpoints for transcatheter aortic valve implantation
clinical trials: a consensus report from the Valve Academic Research
Consortium. Eur Heart J 2011;32:205–217.
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[13, 14], we do not know yet if the same procedure in
extreme-risk proﬁle patients also guarantees acceptable results
in terms of procedural risk, ameliorated quality of life and,
perhaps, longer life-expectancy. Therefore, we studied 40 con-
secutive TA-TAVR patients with logistic EuroSCORE above 35%. In
comparing our results with the (limited) literature, we observe
that Thielmann et al. [15] also identiﬁed 39 patients at extreme
risk who underwent TAVR (24 transapical and 15 transfemoral)
with a mean logistic EuroSCORE of 44 ± 12%. They showed a
30-day mortality of 18% in the entire group and 21% in the
transapical group (in our experience, the 30-day mortality was
15% and the hospital mortality 20%), a 6-month survival rate of
74% in the entire group and 70% in the transapical group, and a
12-month survival rate of 64% in the entire group and 62% in
the transapical group. Moreover, the transfemoral and the trans-
apical populations showed different mean EuroSCORE proﬁles:
38 and 52%, respectively. This difference was statistically signiﬁ-
cant (P < 0.001) and conﬁrmed the higher challenges in perform-
ing TA-TAVR than transfemoral TAVR.
If we compare our group with standard TA-TAVR patients, we
observe that there are better hospital outcomes and mid-term
results as soon as the mean logistic EuroSCORE decreases from
above 40 to 30%. A paper from Walther et al. [16] describes the
mid-term outcome of 299 standard transapical patients with a
mean EuroSCORE of 31 ± 16%: the 30-day mortality was reported
at 9%, and the 1- and 2-year survival rates were 73 and 68%, re-
spectively. Similarly, the PARTNER trial in its transapical arm (104
patients) with a mean logistic EuroSCORE of 32% showed a
30-day mortality of 4% with a 1-year survival rate of 71% [14].
With respect to predictors for hospital mortality, we did not
observe a statistical signiﬁcance for any of the collected pre-
operative variables (due, probably, to the limited amount of
patients), and this conﬁrms that in very high-risk patients groups,
the patient selection performed by the TAVR-team remains
the main predictor for hospital outcomes. Nevertheless, we
observed signiﬁcant P-values for intraoperative and post-
operative complications such as conversion to sternotomy, intra-
procedural life-threatening bleeding, postoperative renal failure
with dialysis and prolonged ICU stay. These ﬁndings are in line
with results from other groups and underline the fragility of
these extreme-risk proﬁle patients: this should always guide the
medical community to carefully evaluate patients who are candi-
dates for TAVR with a reasonable use of bailout procedures in
case of very severe intraprocedural complications. In particular,
the use of contrast for angiographies should be reduced as
much as possible in order to reduce the risk of postoperative
kidney injury, whereas the CPB stand-by can have a remarkable
positive effect for recovery in case of severe haemodynamic in-
stability after an otherwise uncomplicated procedure (typically,
in redo patients after the rapid cardiac pacing).
The concept of ‘frailty’ requires further evaluations also in
order to better quantify the procedural risk: in our experience,
elderly, slim females were reputed to be too fragile to survive
standard surgery but, perhaps, also the adverse events that can
complicate transapical TAVR. In fact, the same phenotype of
patients badly tolerated, in our experience, prolonged ICU stay
and prolonged mechanical ventilation because of the limited
muscular reserve (cachexia) and the consequent higher risk of
pneumonia and MOF. However, after having considered a body
mass index below 20 as a very simple, indirect sign of fragility,
we did not ﬁnd any statistical signiﬁcance for hospital mortality
in our study (limited by the small number of patients) [17].
Figure 3: (A) Survival from all-cause mortality in patients with and without
preoperative coronary angioplasty/stent. (B) Survival from all-cause mortality
in patients with and without paravalvular leaks. (C) Survival from cardiovascu-
lar mortality in patients with and without preoperative coronary angioplasty/
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Concluding, in future TAVR reports, more patients and a more
frailty-focused analysis, with speciﬁc scores, are required to better
deﬁne this point and, in general, we believe that in the process of
adjudicating very high-risk patients to this minimally invasive pro-
cedure we will beneﬁt from new and simple score systems specif-
ically designed for the evaluation of frail candidates.
Concerning the mid-term survival of this limited cohort of
patients (comparable to patients with severe symptomatic AS in
medical therapy [1, 2]), our ﬁndings are in line with the cohort B
of the PARTNER trial, and we can comment that this can be
related to the presence of multiple severe concomitant co-
morbidities and the AVR plays a marginal role in increasing life
expectancy. However, patients alive at FU recall were all in
NYHA class 1–2 with an acceptable quality of life (with respect
of their age), and they were never rehospitalized for cardiac
failure (this reached the goal of the Combined Efﬁcacy Endpoint
at 1 year of the VARC classiﬁcation, together with absence of
signs of stent-valve malfunction).
With respect to risk factors for mid-term all-cause and cardio-
vascular mortality, two characteristics were signiﬁcant for both:
the presence of previous coronary angioplasty and stenting (P =
0.01) and the presence of a residual paravalvular leak after the
TAVR (P = 0.02 and P = 0.01). Moreover, systemic hypertension
(P < 0.00) and previous surgical myocardial revascularization (P =
0.02) have a negative effect on late cardiovascular mortality in
our cohort. Thus, we can assume that the concomitant presence
of a severe coronary disease that already required percutaneous
or surgical revascularization, plays a key role in increasing the
risk of death in very fragile patients treated for AS. On the other
hand, if we take into consideration the paravalvular leak, this is
not the ﬁrst time that residual leaks are related to a higher risk
of mid-term mortality in a group of TA-TAVR patients [18, 19]. In
particular, in our experience the degree of the leakage was eval-
uated by echocardiography both intraoperatively and before the
patient’s discharge and we measured only one Grade 2 and six
Grade 1 leaks: in standard patients, these ﬁndings would not
have represented a severe complication affecting mid-term sur-
vival, whereas very diseased patients do not have the reserve to
support any degree of aortic valve insufﬁciency. Therefore,
further investigations in bigger groups are mandatory to well
deﬁne this crucial point, and we must be more aggressive in
treating leakages.
At the end of these considerations, we should extrapolate a
lesson learned from this cohort of patients at extreme risk, oper-
ated on during a pioneering phase of TAVR procedures. Firstly,
as is well known, all patients must be evaluated by a multidiscip-
linary TAVR-team composed, when the risk score is above 20%
(by EuroSCORE), of a cardiac surgeon, a cardiologist, an anaes-
thetist, and also by an intensivist who evaluates the risk of pro-
longed ICU stay and long intubation time. This ﬁrst phase is
crucial, and doctors should carefully evaluate the ‘biological age’
of these patients using their experience. Secondly, following our
experience, elderly slim women represent a pool of bad candi-
dates even for TAVR because of their increased fragility and
absence of the muscular reserve required to recover in case of
complications or long mechanical ventilation time in ICU.
Thirdly, if the apical access represents a risk of untreatable
haemorrhage (difﬁcult to evaluate preoperatively, but the sur-
geon’s experience plays a role) the TA-TAVR can be aborted and
other access sites, such as the ascending aorta (trans-aortic ap-
proach), should be taken into consideration. Fourthly, the CPB
support can be precious in some critical situations, and the
injection of contrast has to be reduced as much as possible to
prevent renal injury. Fifthly, a more-than trivial paravalvular leak
requires tentative treatment.
In conclusion, TA-TAVR for extreme-risk patients carries a
moderate procedural risk, and patients surviving surgery have a
good quality of life with a low risk of rehospitalization for cardiac
failure. Nevertheless, mid-term survival is affected by multiple
comorbidities and by the presence of residual paravalvular lea-
kages, and is comparable to patients with severe symptomatic
AS under medical treatment.
Limitations of the study
This study has important limitations: (1) it is a retrospective study;
(2) there is no control group because patients with the same char-
acteristics undergoing standard AVR or transfemoral TAVR do not
exist given the extreme-high risk proﬁle; (3) the number of
patients is small with a relatively short FU time (2 years).
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